Voices from China at the EBMT Annual Meeting丨Prof. Peihua Lu / Prof. Wei Zhao: Letermovir Prophylaxis Reshapes Early Immune Reconstitution and CMV/EBV Reactivation Dynamics After Allogeneic HSCT

Voices from China at the EBMT Annual Meeting丨Prof. Peihua Lu / Prof. Wei Zhao: Letermovir Prophylaxis Reshapes Early Immune Reconstitution and CMV/EBV Reactivation Dynamics After Allogeneic HSCT

The 52nd EBMT Annual Meeting was held in Madrid, Spain, from March 22 to 25, 2026. As one of the most influential global conferences in hematopoietic stem cell transplantation, the meeting showcased cutting-edge research and the latest clinical advances in the field.
Voices from China at the EBMT Annual Meeting丨Liu Deyan / Liu Xiaohong: Efficacy of Gemtuzumab Ozogamicin in Relapsed/Refractory AML After Allo-HSCT and Outcomes of Bridging to Second/Third Transplantation — A Retrospective Study

Voices from China at the EBMT Annual Meeting丨Liu Deyan / Liu Xiaohong: Efficacy of Gemtuzumab Ozogamicin in Relapsed/Refractory AML After Allo-HSCT and Outcomes of Bridging to Second/Third Transplantation — A Retrospective Study

Relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) carries an extremely poor prognosis, particularly in patients with high CD33 expression who are refractory to conventional salvage therapies, where treatment options remain very limited.
Insights from the EBMT Annual Meeting丨Prof. Yue Lu on Post-Transplant Relapse in Acute Leukemia: Second Transplantation and Donor Optimization Strategies

Insights from the EBMT Annual Meeting丨Prof. Yue Lu on Post-Transplant Relapse in Acute Leukemia: Second Transplantation and Donor Optimization Strategies

Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains one of the major barriers to long-term survival in acute leukemia. With the rapid development of targeted therapies, hypomethylating agents, and immunotherapies such as CAR-T, salvage treatment options have expanded considerably. As a result, more patients are now able to achieve remission again and proceed to subsequent consolidation strategies.
Prof. Jennifer King: Cabozantinib Breaks Through in Relapsed/Refractory Germ Cell Tumors, Patient-Centered Care Is the Future Core Direction

Prof. Jennifer King: Cabozantinib Breaks Through in Relapsed/Refractory Germ Cell Tumors, Patient-Centered Care Is the Future Core Direction

At the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), breakthroughs in the treatment of relapsed and refractory germ cell tumors emerged as a major focus in the field of genitourinary oncology. Oncology Frontier – UroStream invited Prof. Jennifer King from Indiana University School of Medicine for an in-depth interview, discussing her team’s key research findings, evolving trends in genitourinary cancers, and future directions in clinical development.
Voice of China at EAU26 | Prof. Peng Wu’s Team Wins EAU Oncology Best Abstract Award (Second Prize): Gut Microbiome as a Potential “Compass” for ADC–Immunotherapy in Urothelial Carcinoma

Voice of China at EAU26 | Prof. Peng Wu’s Team Wins EAU Oncology Best Abstract Award (Second Prize): Gut Microbiome as a Potential “Compass” for ADC–Immunotherapy in Urothelial Carcinoma

With the publication of landmark studies such as EV302 and RC48-C016, the combination of antibody–drug conjugates (ADCs) and immunotherapy has firmly established its role as a new standard in the treatment of advanced urothelial carcinoma. Despite these advances, variability in clinical benefit remains evident, highlighting the need to identify more refined predictive biomarkers. 
Voice of China at EAU | Prof. Changbao Xu & Prof. Xiaofu Wang’s Team (The Second Affiliated Hospital of Zhengzhou University) Shine at EAU26 

Voice of China at EAU | Prof. Changbao Xu & Prof. Xiaofu Wang’s Team (The Second Affiliated Hospital of Zhengzhou University) Shine at EAU26 

The 41st Annual Congress of the European Association of Urology (EAU26) was recently held at the ExCeL International Convention Centre in London, UK. As one of the largest and most influential academic gatherings in global urology, the meeting brought together leading experts and scholars from over 100 countries and regions to discuss the latest advances and innovations in clinical practice.
Strategy for Intensification: Efficacy and Safety of BCG Plus ICI in BCG-Naive High-Risk NMIBC Based on 2,590 Patients

Strategy for Intensification: Efficacy and Safety of BCG Plus ICI in BCG-Naive High-Risk NMIBC Based on 2,590 Patients

During the 2026 European Association of Urology (EAU) Congress, Prof. Saad M.A. from the Department of Medical Oncology at the Mohammed V Military Teaching Hospital, Rabat, Morocco, presented a systematic review and reconstructed Individual Patient Data (IPD) meta-analysis. The study evaluated the clinical value of Bacillus Calmette-Guérin (BCG) combined with Immune Checkpoint Inhibitors (ICIs) in BCG-naive patients with high-risk Non-Muscle-Invasive Bladder Cancer (NMIBC).
80% CR Rate! SIM0237 Demonstrates Potent Anti-tumor Activity and Favorable Tolerability in BCG-unresponsive High-risk NMIBC

80% CR Rate! SIM0237 Demonstrates Potent Anti-tumor Activity and Favorable Tolerability in BCG-unresponsive High-risk NMIBC

During a recent academic session, Professor Dingwei Ye (Prof. Dingwei Ye) from Fudan University Shanghai Cancer Center provided an in-depth interpretation of the Phase 1/2 clinical study data for SIM0237—an anti-PD-L1/IL-15 variant fusion protein—specifically in patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC).
52.8% ORR and 87.3% 9-Month PFS Rate: Fruquintinib plus Serplulimab Shows Remarkable Promise in 1st-Line nccRCC 

52.8% ORR and 87.3% 9-Month PFS Rate: Fruquintinib plus Serplulimab Shows Remarkable Promise in 1st-Line nccRCC 

During the recent ASCO GU 2025 (Genitourinary Cancers Symposium), Professor Jiwei Huang from Renji Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine (on behalf of the research team led by Ding Yingjie), presented the updated efficacy and safety data from a multicenter, single-arm, Phase II trial. The study evaluates the combination of Fruquintinib and Serplulimab as a first-line (1st-line) treatment for patients with metastatic or unresectable non-clear cell renal cell carcinoma (nccRCC).
A Predictive Model for BCG-Unresponsiveness and Progression Based on Five Clinical Factors: A Study of 2,211 Patients

A Predictive Model for BCG-Unresponsiveness and Progression Based on Five Clinical Factors: A Study of 2,211 Patients

During a recent session on urological oncology, Professor A. Ślusarczyk from the Department of General, Oncological, and Functional Urology at the Medical University of Warsaw, Poland, presented the results of an international multicenter retrospective study. The study aimed to develop and validate a clinical predictive model to identify patients with high-grade non-muscle-invasive bladder cancer (NMIBC) who are at risk of BCG-unresponsiveness or disease progression following treatment.